ArticleBMC cardiovascular disorders2025
Association between re-elevation of cardiac biomarkers and in-hospital MACE after primary PCI in STEMI patients.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Characteristics and Risk Factors for Major Adverse Cardiovascular Events in Patients on Maintenance Hemodialysis: A Retrospective Study.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPrevious studies have indicated that after reperfusion therapy in patients with myocardial infarction, high-sensitivity cardiac troponin T (hs-cTnT) may exhibit a secondary increase following the initial peak decline, presenting a biphasic pattern. The clinical significance of this second peak remains controversial. Meanwhile, whether creatine kinase-MB (CK-MB) demonstrates a similar secondary increase and its clinical implications have been rarely investigated.
methodsThis retrospective study enrolled patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). The associations of the second increase in the levels of myocardial markers including CK-MB and hs-cTnT and clinical outcomes were analyzed. The main study outcome was the rate of in-hospital major adverse cardiovascular events (MACE), including cardiac death, recurrent AMI, unplanned revascularization and stroke.
resultsA total of 264 patients were included in the study (220 males; average age of 63 ± 12 years). The phenomenon of a second increase in myocardial markers, including hs-cTnT and CK-MB, was observed in a significant subset of patients with STEMI following PPCI: the proportions of patients with isolated hs-cTnT secondary rise, isolated CK-MB secondary rise, and dual secondary rise were 29.9%, 11.7%, and 9.1%, respectively. The incidence of MACE in the isolated hs-cTnT secondary rise group (1.3%) was not significantly different from that in the no secondary rise group (1.5%). In contrast, both the isolated CK-MB secondary rise group (9.7%) and the dual secondary rise group (16.7%) showed higher MACE rates compared to the no secondary rise group.
conclusionsIn conclusion, a secondary rise in CK-MB, whether isolated or concurrent with hs-cTnT, is associated with a significantly higher risk of MACE. In contrast, an isolated secondary rise in hs-cTnT does not appear to confer an increased risk. These findings suggest that CK-MB, rather than hs-cTnT, is a more critical biomarker for identifying the biphasic pattern that predicts adverse outcomes in post-MI patients after reperfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.